Work

Targeting VEGFRi resistance through HIF-1á suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps5614

Authors: Carolyn N. Krasner, Michael J. Birrer, Suzanne T. Berlin, Mary K. Buss, Scott Eliasof, Edward Graeme Garmey, Meliessa Hennessey, Neil S. Horowitz, Panagiotis Konstantinopoulos, Ursula A Matulonis

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Cerulean Pharma (United States), Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597616901

Cites:

Cited by: 1

Related to: 10